330.00
price up icon0.31%   +1.01
after-market  After Hours:  330.00 
loading
ShockWave Medical Inc stock is currently priced at $330.00, with a 24-hour trading volume of 530.76K. It has seen a +0.31% increased in the last 24 hours and a +4.41% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $329.0 pivot point. If it approaches the $330.5 resistance level, significant changes may occur.
Previous Close:
$328.99
Open:
$329
24h Volume:
530.76K
Market Cap:
$12.38B
Revenue:
$730.23M
Net Income/Loss:
$147.28M
P/E Ratio:
51.40
EPS:
6.42
Net Cash Flow:
$165.46M
1W Performance:
+0.30%
1M Performance:
+4.41%
6M Performance:
+59.95%
1Y Performance:
+15.65%
1D Range:
Value
$328.45
$330.28
52W Range:
Value
$157.00
$331.58

ShockWave Medical Inc Stock (SWAV) Company Profile

Name
Name
ShockWave Medical Inc
Name
Phone
510-279-4262
Name
Address
5403 Betsy Ross Drive, Santa Clara
Name
Employee
162
Name
Twitter
@ShockwaveIVL
Name
Next Earnings Date
2024-05-06
Name
Latest SEC Filings
Name
SWAV's Discussions on Twitter

ShockWave Medical Inc Stock (SWAV) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-29-23 Initiated UBS Neutral
Jul-10-23 Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-23 Resumed Morgan Stanley Equal-Weight
Mar-15-23 Initiated Needham Buy
Dec-16-22 Initiated Deutsche Bank Buy
Dec-12-22 Downgrade Wells Fargo Overweight → Equal Weight
Sep-06-22 Downgrade Oppenheimer Perform → Underperform
Apr-06-22 Initiated Wolfe Research Outperform
Mar-02-22 Resumed BofA Securities Buy
Dec-06-21 Upgrade Wells Fargo Equal Weight → Overweight
Jul-15-21 Initiated SVB Leerink Outperform
Jul-12-21 Downgrade BofA Securities Buy → Neutral
Jun-18-21 Downgrade Wells Fargo Overweight → Equal Weight
May-11-21 Upgrade BofA Securities Neutral → Buy
May-11-21 Upgrade Piper Sandler Neutral → Overweight
Jan-20-21 Downgrade Piper Sandler Overweight → Neutral
Dec-01-20 Downgrade BofA Securities Buy → Neutral
Jun-11-20 Upgrade Oppenheimer Underperform → Perform
Apr-01-20 Downgrade Oppenheimer Perform → Underperform
Feb-21-20 Upgrade BofA/Merrill Neutral → Buy
Dec-12-19 Upgrade Wells Fargo Market Perform → Outperform
Oct-22-19 Initiated Oppenheimer Perform
Oct-21-19 Initiated Piper Jaffray Overweight
Jun-13-19 Reiterated BofA/Merrill Neutral
Apr-01-19 Initiated BofA/Merrill Neutral
Apr-01-19 Initiated Morgan Stanley Equal-Weight
Apr-01-19 Initiated Wells Fargo Market Perform
View All

ShockWave Medical Inc Stock (SWAV) Financials Data

ShockWave Medical Inc (SWAV) Revenue 2024

SWAV reported a revenue (TTM) of $730.23 million for the quarter ending December 31, 2023, a +49.11% rise year-over-year.
loading

ShockWave Medical Inc (SWAV) Net Income 2024

SWAV net income (TTM) was $147.28 million for the quarter ending December 31, 2023, a -31.81% decrease year-over-year.
loading

ShockWave Medical Inc (SWAV) Cash Flow 2024

SWAV recorded a free cash flow (TTM) of $165.46 million for the quarter ending December 31, 2023, a +78.67% increase year-over-year.
loading

ShockWave Medical Inc (SWAV) Earnings per Share 2024

SWAV earnings per share (TTM) was $3.87 for the quarter ending December 31, 2023, a -32.11% decline year-over-year.
loading

ShockWave Medical Inc Stock (SWAV) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
FRANCIS LAURA
Director
Mar 26 '24
Option Exercise
6.59
1,500
9,882
2,733
Zacharias Isaac
President, CCO
Mar 26 '24
Sale
287.67
4,000
1,150,680
56,818
FRANCIS LAURA
Director
Mar 26 '24
Sale
300.00
1,500
450,000
3,551
WATKINS FRANK T
Director
Mar 06 '24
Option Exercise
3.42
2,000
6,832
6,532
WATKINS FRANK T
Director
Mar 06 '24
Sale
253.65
2,000
507,294
4,532
Phung Trinh
VP, Finance
Mar 06 '24
Sale
253.14
21
5,316
31,024
Zacharias Isaac
President, CCO
Feb 26 '24
Sale
260.36
4,000
1,041,440
61,372
Phung Trinh
VP, Finance
Feb 22 '24
Sale
259.24
599
155,285
31,031
MOLL FREDERIC H
Director
Feb 21 '24
Sale
257.39
60,000
15,443,412
287,521
FRANCIS LAURA
Director
Feb 16 '24
Option Exercise
6.59
1,000
6,588
2,233
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
medical_devices PHG
$21.07
price up icon 1.69%
medical_devices STE
$203.90
price up icon 1.17%
$309.02
price down icon 0.48%
medical_devices ZBH
$119.35
price down icon 0.33%
$124.34
price down icon 9.91%
medical_devices EW
$86.43
price down icon 1.80%
Cap:     |  Volume (24h):